Avalo Therapeutics Files 8-K
Ticker: AVTX · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, corporate-filing, financials
Related Tickers: AVLO
TL;DR
AVLO filed an 8-K on 10/10/25 for other events and financials.
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on October 10, 2025, reporting other events and financial statements. The company, formerly known as Cerecor Inc. until November 2, 2011, is incorporated in Delaware and headquartered in Wayne, Pennsylvania.
Why It Matters
This filing indicates routine corporate reporting, providing updates on events and financial statements for Avalo Therapeutics, Inc.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 001-37590 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-0705648 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- October 10, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Wayne, Pennsylvania (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Avalo Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 10, 2025.
When did Avalo Therapeutics, Inc. change its name from Cerecor Inc.?
Avalo Therapeutics, Inc. changed its name from Cerecor Inc. on November 2, 2011.
In which state is Avalo Therapeutics, Inc. incorporated?
Avalo Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Avalo Therapeutics, Inc.?
The business address of Avalo Therapeutics, Inc. is 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.
What is the SEC file number for Avalo Therapeutics, Inc.?
The SEC file number for Avalo Therapeutics, Inc. is 001-37590.
Filing Stats: 420 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-10-10 07:01:40
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20251010.htm (8-K) — 25KB
- ex-991avalocorporatepres.htm (EX-99.1) — 28KB
- ex-991avalocorporatepres001.jpg (GRAPHIC) — 116KB
- ex-991avalocorporatepres002.jpg (GRAPHIC) — 233KB
- ex-991avalocorporatepres003.jpg (GRAPHIC) — 161KB
- ex-991avalocorporatepres004.jpg (GRAPHIC) — 129KB
- ex-991avalocorporatepres005.jpg (GRAPHIC) — 76KB
- ex-991avalocorporatepres006.jpg (GRAPHIC) — 112KB
- ex-991avalocorporatepres007.jpg (GRAPHIC) — 95KB
- ex-991avalocorporatepres008.jpg (GRAPHIC) — 124KB
- ex-991avalocorporatepres009.jpg (GRAPHIC) — 132KB
- ex-991avalocorporatepres010.jpg (GRAPHIC) — 107KB
- ex-991avalocorporatepres011.jpg (GRAPHIC) — 110KB
- ex-991avalocorporatepres012.jpg (GRAPHIC) — 152KB
- ex-991avalocorporatepres013.jpg (GRAPHIC) — 141KB
- ex-991avalocorporatepres014.jpg (GRAPHIC) — 122KB
- ex-991avalocorporatepres015.jpg (GRAPHIC) — 148KB
- ex-991avalocorporatepres016.jpg (GRAPHIC) — 61KB
- ex-991avalocorporatepres017.jpg (GRAPHIC) — 191KB
- ex-991avalocorporatepres018.jpg (GRAPHIC) — 135KB
- ex-991avalocorporatepres019.jpg (GRAPHIC) — 51KB
- ex-991avalocorporatepres020.jpg (GRAPHIC) — 43KB
- ex-991avalocorporatepres021.jpg (GRAPHIC) — 88KB
- 0001534120-25-000011.txt ( ) — 3682KB
- avtx-20251010.xsd (EX-101.SCH) — 2KB
- avtx-20251010_def.xml (EX-101.DEF) — 14KB
- avtx-20251010_lab.xml (EX-101.LAB) — 24KB
- avtx-20251010_pre.xml (EX-101.PRE) — 15KB
- avtx-20251010_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 10, 2025, Avalo Therapeutics, Inc. posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Investor Presentation. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: October 10, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2